Study of all data on Roche's highly debated Tamiflu says it does help

A significant new study of Roche's ($RHHBY) blockbuster flu fighter Tamiflu has found that, while it has side effects, it can reduce symptoms by a day and keep some patients out of the hospital with complications, Reuters reports. The drug, which was heavily stockpiled by governments during a swine flu scare in 2009, has been hotly debated with contentions that it just doesn't do much. The new analysis, published in The Lancet on Friday, evaluated the data from all previously published and unpublished trials of Tamiflu. Story | More

Suggested Articles

It’s been a rocky road for BMS’ immuno-oncology duo in previously untreated lung cancer, but a new addition to the regimen might hold the ticket.

Novartis’ Zolgensma launch has been anything but boring: First a record price, then a data scandal and now a manufacturing-related delay in Europe.

As CEO Paul Hudson focuses Sanofi's R&D program on immuno-oncology and gene therapies, Sanofi is readying a vaccine plant to make viral vectors.